Will Axonics Square Up To Medtronic In Sacral Neuromodulation Market?
This article was originally published in Clinica
Signaling its entry into a small but fast-growing segment of the implantable neurostimulation market, Axonics Modulation Technologies has CE marked its sacral neuromodulation (SNM) system for treating overactive bladder (OAB), fecal incontinence and urinary retention. It is the first device of its kind to be rechargeable, significantly extending its longevity and giving Axonics what it believes to be a clinical and economic advantage over rivals such as medtech heavyweight Medtronic, which has been in this market since the late 1990s with its Interstim system.
Register for our free email digests: